Miyajima Y, Horibe K, Fukuda M, Matsumoto K, Numata S, Mori H, Kato K
Department of Pediatrics, Nagoya University School of Medicine, Japan.
Cancer. 1996 Mar 15;77(6):1214-9. doi: 10.1002/(sici)1097-0142(19960315)77:6<1214::aid-cncr31>3.0.co;2-2.
The aim of this study was to evaluate the changes of tumor cell contamination in bone marrow (BM) and peripheral blood (PB) during the clinical course of patients with advanced neuroblastoma by detecting tyrosine hydroxylase (TH) mRNA to clarify the appropriate source and time for harvesting hematopoietic stem cells for transplantation.
A total of 15 patients with Stage IV neuroblastoma were studied. All 15 patients had peripheral blood stem cell (PBSC) samples and BM samples examined for TH mRNA by using the reverse transcription-polymerase chain reaction (RT-PCR) at the time of harvest. Nine of the 15 patients, also had BM and PB samples examined sequentially.
Comparing the 45 paired samples concurrently drawn, 16 of 28 BM samples (57.1%) and 4 of 28 PB samples (14.2%) obtained during complete remission (CR) were positive for TH mRNA (P < 0.01), whereas 17 of 17 BM samples (100%) and 14 of 17 PB samples (82.3%) obtained before CR was achieved were positive (not significant). The incidence of TH mRNA positivity was significantly lower in the samples obtained during CR than those obtained before CR was achieved (P < 0.0001 for PB samples, P < 0.01 for BM samples). At the time of PBSC harvesting, the incidence of TH mRNA positivity was lower in PBSC samples (3 of 15, 20%) than in BM samples obtained concurrently (10 of 15, 66.7%; P < 0.03).
These findings show that there is a substantial risk of tumor cell contamination in harvested PBSCs, although its incidence was lower than that in BM samples. We recommend that PBSCs would be better harvested during remission and should be examined for tumor contamination before use as a stem cell source.
本研究旨在通过检测酪氨酸羟化酶（TH）mRNA，评估晚期神经母细胞瘤患者临床病程中骨髓（BM）和外周血（PB）中肿瘤细胞污染的变化，以明确采集造血干细胞进行移植的合适来源和时间。
共研究了15例IV期神经母细胞瘤患者。所有15例患者在采集时均采集了外周血干细胞（PBSC）样本和BM样本，采用逆转录聚合酶链反应（RT-PCR）检测TH mRNA。15例患者中的9例还对BM和PB样本进行了连续检测。
比较同时采集的45对样本，完全缓解（CR）期间获得的28份BM样本中有16份（57.1%）和28份PB样本中有4份（14.2%）TH mRNA呈阳性（P < 0.01），而在达到CR之前获得的17份BM样本中有17份（100%）和17份PB样本中有14份（82.3%）呈阳性（无显著性差异）。CR期间获得的样本中TH mRNA阳性发生率显著低于达到CR之前获得的样本（PB样本P < 0.0001，BM样本P < 0.01）。在采集PBSC时，PBSC样本中TH mRNA阳性发生率（15份中的3份，20%）低于同时采集的BM样本（15份中的10份，66.7%；P < 0.03）。
这些发现表明，采集的PBSC中存在肿瘤细胞污染的重大风险，尽管其发生率低于BM样本。我们建议在缓解期采集PBSC，并在用作干细胞来源之前检查肿瘤污染情况。
